This trial is active, not recruiting.

Condition breast cancer
Treatment brca testing and questionnaire assessments
Sponsor Memorial Sloan Kettering Cancer Center
Start date June 2011
End date June 2018
Trial size 108 participants
Trial identifier NCT01386411, 11-086


Genes are the "blueprints" for our bodies. Some people are born with an abnormal copy ("mutation") of a gene. These people may have a higher chance of getting a disease. Different mutations in different genes cause different diseases. Some women get breast cancer because they are born with an abnormal copy of a gene called BRCA1 or BRCA2. These women also have a higher chance of getting ovary cancer. Women with breast cancer and an abnormal copy of BRCA1 or BRCA2 also have a higher chance of getting a second breast cancer in their other breast. Because of this, women who might have a mutation may have genetic testing soon after their breast cancer diagnosis to learn about their risks of getting another cancer.

Genetic testing may be done right after a woman has been diagnosed with breast cancer. It may also be done later, after surgery is done to treat the cancer. The investigators do not know when it is best to do genetic testing. The investigators are doing this study to try to understand whether women prefer testing before or after surgery. The investigator also want to find out how they feel about their choice later on, when their diagnosis in more in their past.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model family-based
Time perspective prospective
The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
brca testing and questionnaire assessments
If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.

Primary Outcomes

To determine the relative proportions of women offered genetic testing after a breast cancer diagnosis who decide to have BRCA testing
time frame: 2 years

Secondary Outcomes

To determine the relative proportions of women who decide to undergo prophylactic mastectomy (PM)
time frame: 2 years
To assess the factors associated with the decision to choose pre- or post surgical testing.
time frame: 2 years

Eligibility Criteria

Female participants from 18 years up to 50 years old.

Inclusion Criteria: - Diagnosis of invasive breast cancer or DCIS - Appropriate for genetic testing, defined as if they meeting one or more of the following criteria (note that patients may be appropriate for genetic testing even if they do not meet these criteria, but NCCN and most payers recognize these groups as clearly appropriate for testing) - Must be a primary malignancy (not recurrence), but can be second diagnosis if is a contralateral cancer and the first cancer was not treated with mastectomy - Female age ≥18, - If Ashkenazi Jewish: Breast cancer diagnosis ≤ 60. Subjects will be presumed to be of Ashkenazi ethnicity if Jewish religious preference is confirmed in subject and at least 1 parent, unless they explicitly endorse Sephardic, Iranian, Yemeni/Ethiopian, or Bukharan Jewish Decent, in which case non-Ashkenazi criteria will be applied. If not Ashkenazi Jewish: - Breast cancer diagnosis ≤ 45 OR - Bilateral breast cancer, with first diagnosed ≤ 50 OR - Breast cancer diagnosed at any age with a male relative with breast cancer OR - Breast cancer diagnosis ≤ 50 with one or more of the following:: - 1 or more relative with breast cancer ≤ 50 or - 1 or more relative with ovarian cancer - Have not completed definitive surgical treatment - For patients planning mastectomy for treatment, has not yet undergone mastectomy - For patients planning breast conservation for treatment, has not yet begun adjuvant radiation therapy Exclusion Criteria: - LCIS without invasive cancer (IDC or ILC) and without DCIS - Previous breast cancer treated with mastectomy - Plan for neoadjuvant chemotherapy before surgery - Unable to complete English language questionnaires, as instruments have not been validated in non-English speaking populations

Additional Information

Official title Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer
Principal investigator Mark Robson, MD
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center.